Lonza cited increasing demand for clinical-stage manufacturing and said “the acquisition of the site will provide additional cGMP capacity and will ...
Lonza cited increasing demand for clinical-stage manufacturing and said “the acquisition of the site will provide additional cGMP capacity and will ...
... therapies to target solid tumors, announces that the US Patent and Trademark Office has granted US Patent no 9,775,892, Peptide mixture.
ITCA 650 is an implantable pump designed to deliver a continuous supply of the glucagon-like peptide-1 agonist exenatide, which is the active ...
Lutathera, a peptide receptor radionuclide therapy, is the company's first drug approved as a therapeutic drug for GEP-NET. However, Advanced ...
BL-8040 is a short peptide for the treatment of acute myeloid leukemia, solid tumors and certain hematological indications. It functions as a high-affinity ...
... for hypoparathyroidism currently in a phase 1 trial, and TransCon CNP, a long-acting prodrug of C-type Natriuretic Peptide for achondroplasia.
Rhythm Pharmaceuticals, a clinical-stage biotech developing peptide-based therapies to treat genetic obesity, announced terms for its IPO on Monday ...
... with a combination of our long-acting GLP-1 receptor agonist plus a glucagon or GIP (glucose-dependent insulinotropic peptide) receptor agonist.
Reltecimod (AB103) is a rationally designed peptide that binds to the CD28 co-stimulatory receptor to modulate the host's immune response to severe ...
Numaferm claims it can make peptides at 1/1,000th of the price of standard chemical process costs (about $1.2 million per kg). Numaferm's technology ...